GC
PTGX icon

Gratus Capital’s Protagonist Therapeutics PTGX Stock Holding History

Gratus Capital’s Portfolio PTGX Stock Details PTGX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		$14.5M Buy
418,346
+10,173
+2% +$298K 0.58% 53
2024
Q1 		$11.8M Buy
408,173
+10,602
+3% +$288K 0.54% 60
2023
Q4 		$9.12M Buy
397,571
+104,702
+36% +$1.83M 0.51% 64
2023
Q3 		$4.89M Buy
292,869
+73,283
+33% +$1.42M 0.33% 77
2023
Q2 		$6.06M Buy
219,586
+7,855
+4% +$197K 0.41% 70
2023
Q1 		$4.87M Sell
211,731
-7,328
-3% -$123K 0.37% 67
2022
Q4 		$2.39M Buy
219,059
+12,946
+6% +$109K 0.2% 81
2022
Q3 		$1.74M Buy
+206,113
New +$1.95M 0.18% 91

Other funds holding PTGX

FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
JJ
Johnson & Johnson New Brunswick, New Jersey $652M AUM 198.07% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
JFG
Jefferies Financial Group New York $14.6B AUM 40.95% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
ACM
ADAR1 Capital Management Austin, Texas $1.7B AUM 340.85% 1-Year Est. Return

Gratus Capital's PTGX Position: Q2 2024 in Review

Gratus Capital increased its Protagonist Therapeutics (PTGX) stake by 2.5% in Q2 2024, buying an estimated $298K and bringing the position to 418,346 shares worth $14.5M. The position accounts for 0.58% of the portfolio, ranked #53.

Gratus Capital first reported a position in PTGX in Q3 2022 and has held it in 8 quarters since. 188 funds tracked by Wall St. Rank hold PTGX as of Q2 2024.

  • Gratus Capital held 418,346 shares of Protagonist Therapeutics worth $14.5M as of Q2 2024.
  • Gratus Capital bought 10,173 Protagonist Therapeutics shares in Q2 2024, an estimated $298K.
  • Protagonist Therapeutics made up 0.58% of Gratus Capital's portfolio in Q2 2024, its #53 holding.
  • Gratus Capital first reported a position in Protagonist Therapeutics in Q3 2022 and has held it in 8 quarters since.
  • 188 funds tracked by Wall St. Rank held Protagonist Therapeutics as of Q2 2024.

Based on Gratus Capital's 13F filing for Q2 2024, filed 25 Jul 2024.